期刊
JOURNAL OF RENAL CARE
卷 38, 期 -, 页码 67-77出版社
WILEY
DOI: 10.1111/j.1755-6686.2012.00281.x
关键词
Anaemia; Cardiovascular disease; Chronic kidney disease; Diabetes; Erythropoiesis-stimulating agents; Erythropoietin; Hospitalisation; Iron; Mortality; Quality of life
Anaemia is a common finding in people with diabetes and chronic kidney disease and failure of the kidney to produce erythropoietin in response to a falling haemoglobin concentration is a key component, correlating with the degree of albuminuria, renal dysfunction and iron deficiency. Anaemia in diabetes is associated with a number of adverse outcomes, including increased risk of all cause and cardiovascular mortality. Whether or not anaemia is a marker or mediator of adverse outcome still remains to be completely resolved. Treatment of anaemia in diabetes has quality of life benefits and reduces transfusion requirements. Correction of anaemia to normal haemoglobin concentrations is associated with significant adverse cardiovascular outcomes and is not recommended, escalating doses of erythropoiesis-stimulating agents should be avoided. The treatment of anaemia in people with diabetes and chronic kidney disease should begin with optimisation of iron stores. An aspirational haemoglobin concentration range of 10-12 g/dl with anaemia management, balances proven benefits of anaemia treatment with potential cardiovascular risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据